FY2025 EPS Estimates for Adicet Bio Reduced by HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share estimates for Adicet Bio in a research note issued on Wednesday, January 21st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($18.36) per share for the year, down from their prior estimate of ($18.08). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio’s Q4 2025 earnings at ($3.59) EPS, Q1 2026 earnings at ($2.91) EPS, Q2 2026 earnings at ($3.00) EPS, Q3 2026 earnings at ($3.08) EPS, Q4 2026 earnings at ($3.17) EPS and FY2026 earnings at ($12.17) EPS.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adicet Bio in a research note on Thursday, October 30th. Jefferies Financial Group raised shares of Adicet Bio to a “strong-buy” rating in a report on Tuesday, October 7th. Canaccord Genuity Group set a $18.00 target price on shares of Adicet Bio and gave the company a “buy” rating in a report on Tuesday, January 6th. Guggenheim increased their target price on shares of Adicet Bio from $112.00 to $128.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Finally, Wedbush reissued an “outperform” rating and issued a $80.00 price target on shares of Adicet Bio in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $69.00.

Adicet Bio Trading Up 0.5%

Shares of Adicet Bio stock opened at $8.44 on Friday. The company has a current ratio of 5.62, a quick ratio of 5.62 and a debt-to-equity ratio of 0.01. The firm’s 50 day simple moving average is $8.51 and its two-hundred day simple moving average is $11.05. The firm has a market capitalization of $80.86 million, a price-to-earnings ratio of -0.42 and a beta of 1.60. Adicet Bio has a 12-month low of $7.15 and a 12-month high of $17.44.

Adicet Bio (NASDAQ:ACET) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($4.64) EPS for the quarter, missing the consensus estimate of ($4.16) by ($0.48).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. raised its holdings in shares of Adicet Bio by 33.3% in the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company’s stock valued at $49,000 after buying an additional 20,000 shares during the last quarter. Wealthedge Investment Advisors LLC raised its stake in Adicet Bio by 37.4% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 313,108 shares of the company’s stock valued at $191,000 after acquiring an additional 85,307 shares during the last quarter. Citadel Advisors LLC lifted its position in Adicet Bio by 19.8% during the 3rd quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock worth $473,000 after acquiring an additional 96,342 shares during the period. Two Sigma Investments LP grew its stake in shares of Adicet Bio by 66.6% in the 3rd quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock valued at $692,000 after purchasing an additional 341,761 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Adicet Bio by 1.7% in the first quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock valued at $2,882,000 after purchasing an additional 63,691 shares during the period. 83.89% of the stock is owned by hedge funds and other institutional investors.

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.